55076-32-9

Usage

Uses

Used in Synthetic Preparations:
Methyl 3-hydroxy-5-nitro-benzoate is used as an intermediate in the synthesis of various organic compounds. Its unique functional groups make it a versatile building block for creating a range of chemical products.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, methyl 3-hydroxy-5-nitro-benzoate is used as a key component in the development of new drugs. Its chemical structure allows for the creation of novel molecules with potential therapeutic applications.
Used in Chemical Research:
Methyl 3-hydroxy-5-nitro-benzoate is also utilized in chemical research for studying reaction mechanisms and exploring new synthetic pathways. Its reactivity and functional group chemistry provide valuable insights into organic chemistry and contribute to the advancement of the field.

InChI:InChI=1/C8H7NO5/c1-14-8(11)5-2-6(9(12)13)4-7(10)3-5/h2-4,10H,1H3

Upstream product

• 67-56-1 methanol 
• 78238-14-9 3-hydroxy-5-nitrobenzoic acid 
• 618-84-8 3-amino-5-nitro-benzoic acid 
• 99-34-3 3,5-dinitrobenzoic acid 
• 117342-20-8 (3-(methoxycarbonyl)-5-nitrophenyl)boronic acid 

Downstream Products

• 875846-14-3 3-butoxy-5-nitro-benzoic acid 
• 92010-01-0 methyl α-(tert-butoxycarbonyl)-5-nitro-m-anisate 
• 1375150-05-2 methyl 3-(cyclopropylmethoxy)-5-nitrobenzoate 
• 1375150-06-3 C₁₃H₁₇NO₅ 
• 1375150-04-1 C₁₁H₁₁NO₅ 
• 1375150-03-0 methyl 3-ethoxy-5-nitrobenzoate 
• 1375150-07-4 methyl 3-[(1-methylethyl)oxy]-5-nitrobenzoate 
• 444343-60-6 Methyl 3-[(2-naphthyl)methoxy]-5-nitrobenzoate 
• 156449-65-9 3-nitro-5-(octadecyloxy)benzoic acid methyl ester 
• 1445880-78-3 methyl 3-(7-(2,4-dimethoxypyrimidin-5-yl)-2-methyl-3-(N-methylsulfamoyl)quinolin-4-ylamino)-5-isopropoxybenzoate 
• 1445879-72-0 3-((7-(2,4-dimethoxypyrimidin-5-yl)-2-methyl-3-(N-methylsulfamoyl)quinolin-4-yl)amino)-5-isopropoxybenzoic acid 
• 1445880-75-0 methyl 3-(3-(N-cyclopropylsulfamoyl)-7-(2,4-dimethoxypyrimidin-5-yl)-2-methylquinolin-4-ylamino)-5-isopropoxybenzoate 
• 1445879-70-8 3-((3-(N-cyclopropylsulfamoyl)-7-(2,4-dimethoxypyrimidin-5-yl)-2-methylquinolin-4-yl)amino)-5-isopropoxybenzoic acid 
• 1445880-66-9 methyl 3-(7-(2,4-dimethoxypyrimidin-5-yl)-3-(N-oxetan-3-ylsulfamoyl)quinolin-4-ylamino)-5-isopropoxybenzoate 

Relevant academic research and scientific papers

Discovery and Structure-Activity Relationships of the Neoseptins: A New Class of Toll-like Receptor-4 (TLR4) Agonists

Herein, we report studies leading to the discovery of the neoseptins and a comprehensive examination of the structure-activity relationships (SARs) of this new class of small-molecule mouse Toll-like receptor 4 (mTLR4) agonists. The compounds in this class, which emerged from screening an α-helix mimetic library, stimulate the immune response, act by a well-defined mechanism (mouse TLR4 agonist), are easy to produce and structurally manipulate, exhibit exquisite SARs, are nontoxic, and elicit improved and qualitatively different responses compared to lipopolysaccharide, even though they share the same receptor.

Ruthenium-Catalyzed Hydroarylation and One-Pot Twofold Unsymmetrical C?H Functionalization of Arenes

A methyl phenyl sulfoximine (MPS) is used as a directing group in the ruthenium-catalyzed intramolecular hydroarylation of alkene-tethered benzoic acid derivatives to afford dihydrobenzofurans and indolines in good to excellent yields. A one-pot, unsymmetrical, twofold C?H functionalization involving intramolecular C?C and intermolecular C?C/C?N bond formations is successfully demonstrated by using a single set of catalytic reaction conditions, which is unprecedented thus far. A novel isoquinolone-bearing dihydrobenzofuran is constructed through an unsymmetrical twofold C?H functionalization.

NEOSEPTINS: SMALL MOLECULE ADJUVANTS

A MD-2:TLR4 complex agonist compound is disclosed whose structure corresponds to Formula (I), as defined within. Also disclosed are a method of its preparation and use, as well as a pharmaceutical composition containing the same.

CRYSTALLINE FORMS OF TRICYCLIC COMPOUND ACID SALT OR HYDRATE THEREOF, AND METHOD FOR MAKING THEREOF

The present invention relates to a novel crystalline acid salt of a tricyclic derivative or a hydrate thereof and a production method thereof. The crystalline acid salt or the hydrate thereof according to the present invention is stable with respect to hu

HETEROCYCLIC DERIVATIVES AND USE THEREOF

A heterocyclic derivative represented by formula (I), or a pharmaceutically acceptable salt or a stereoisomer thereof, which has an inhibitory effect on the activation of STAT3 protein, and is useful for the prevention or treatment of diseases associated with the activation of STAT3 protein.

IMIDAZOPYRIDINE COMPOUNDS

Compounds, pharmaceutical compositions, kits and methods are provided for use with glucokinase that comprise a compound selected from the group consisting of formula (I) wherein the variables are as defined herein.

BENZAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS

The present invention provides novel benzamide derivatives of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables A, W, Y, Z, R8, and R9 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.

Trisubstituted carbocyclic cyclophilin binding compounds and their use

The present invention relates to novel, non-peptidic small organic compounds having an affinity for cyclophilin (CyP)-type immunophilin proteins, and to pharmaceutical compositions comprising one or more of the said compounds. The invention further relates to the uses of these compounds and compositions for binding CyP-type proteins, inhibiting their peptidyl-prolyl isomerase activity, and for research, development, and therapeutic applications in a variety of medical disorders.

Design, synthesis, and testing of potential antisickling agents. 5. Disubstituted benzoic acids designed for the donor site and proline salicylates designed for the acceptor site

This paper reports the discovery of a new class of potent antigelling agents. The new compounds, disubstituted benzoic acid derivatives, were designed by using molecular modeling experiments. These molecules contain functional groups positioned to interac